<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03461757</url>
  </required_header>
  <id_info>
    <org_study_id>BHV3000-303</org_study_id>
    <nct_id>NCT03461757</nct_id>
  </id_info>
  <brief_title>Trial in Adult Subjects With Acute Migraines</brief_title>
  <official_title>BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biohaven Pharmaceutical Holding Company Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biohaven Pharmaceutical Holding Company Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus
      placebo in subjects with Acute Migraines.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Anticipated">August 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 3, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain freedom of rimegepant compared with placebo in the acute treatment of migraine will be measured using the number of evaluable subjects that report no pain at 2 hours post-dose.</measure>
    <time_frame>Two hours post dose</time_frame>
    <description>Pain will be measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from the most bothersome symptom (MBS) of rimegepant compared with placebo will be measured using the number of evaluable subjects that report the absence of their MBS at 2 hours post-dose.</measure>
    <time_frame>Two hours post dose</time_frame>
    <description>The MBS (nausea, phonophobia or photophobia) will measured using a binary scale (0=absent, 1=present).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rimegepant compared to placebo from 2 to 24 hours, using the number of subjects that do not experience any headache pain through the time period of interest.</measure>
    <time_frame>2 hours -24 hours post-dose</time_frame>
    <description>Sustained Pain Freedom as measured by a 4 point numeric rating scale (None, Mild, Moderate, Severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rimegepant compared to placebo by tabulating the number of subjects that report the absence of photophobia at 2 hours post-dose in the subset of subjects that reported the presence of photophobia at headache baseline</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>Freedom from Photophobia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rimegepant compared to placebo by tabulating the number of subjects that report the absence of phonophobia at 2 hours post-dose in the subset of subjects that reported the presence of phonophobia at headache baseline</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>Freedom from Phonophobia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure rimegepant compared to placebo on Pain Relief, at 2 hours post-dose, that report a pain level of moderate or severe at baseline and then report a pain level of none or mild.</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>Pain Relief as measured by a 4 point numeric rating scale (None, Mild, Moderate, Severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Nausea will by tabulating the number of subjects that report the absence of nausea at 2 hours post-dose in the subset of subjects that reported the presence of nausea at headache baseline.</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>Freedom from Nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure rimegepant compared to placebo on the probability of requiring rescue medication will be assessed using the number of subjects that take rescue medication within 24 after administration of study medication (BHV3000 or placebo).</measure>
    <time_frame>up to 24 hours post-dose</time_frame>
    <description>Requiring Rescue Medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rimegepant compared to placebo on sustained pain freedom, from 2 to 48 hours, will be measured using the number of subjects that do not experience any headache pain through the time period of interest.</measure>
    <time_frame>2 hours - 48 hours post-dose</time_frame>
    <description>Sustained Pain Freedom as measured by a 4 point numeric rating scale (None, Mild, Moderate, Severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rimegepant compared to placebo on sustained pain relief, from 2 to 24 hours by using the number of subjects that do not use any rescue medications, and do not experience any moderate or severe headache pain through that time.</measure>
    <time_frame>2 hours- 24 hours post-dose</time_frame>
    <description>Sustained Pain Relief as measured by a 4 point numeric rating scale (None, Mild, Moderate, Severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rimegepant compared to placebo on sustained pain relief from 2 to 48 hours, using the number of subjects that do not use any rescue medications and do not experience moderate to severe headache pain.</measure>
    <time_frame>2 hours - 48 hours post-dose</time_frame>
    <description>Sustained Pain Relief as measured by a 4 point numeric rating scale (None, Mild, Moderate, Severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional disability scale</measure>
    <time_frame>2 hour post-dose</time_frame>
    <description>Subjects self-report &quot;normal&quot; on the functional disability scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the number of subjects that are pain free at 2 hours post-dose and then have a headache of any severity (response of 1, 2 or 3 on the 4-point scale within 48 hours after administrations of study medication, rimegepant or placebo.</measure>
    <time_frame>2 hours - 48 hours post-dose</time_frame>
    <description>Pain relapse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Arm 1: BHV-3000 (Active)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Placebo Comparator Drug</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimegepant</intervention_name>
    <description>BHV-3000 (rimegepant) 75 mg (ODT)</description>
    <arm_group_label>Arm 1: BHV-3000 (Active)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>75mg matching placebo ODT</description>
    <arm_group_label>Arm 2: Placebo Comparator Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Subject has at least 1 year history of migraines (with or without aura), consistent with
        a diagnosis according to the International Classification of Headache Disorder, 3rd
        Edition, Beta version [1] including the following:

          1. Migraine attacks present for more than 1 year with the age of onset prior to 50 years
             of age

          2. Migraine attacks, on average, lasting about 4-72 hours if untreated

          3. Not more than 8 attacks of moderate to severe intensity per month within the last 3
             months

          4. Consistent migraine headaches of at least 2 migraine headache attacks of moderate or
             severe intensity in each of the 3 months prior to the Screening Visit and maintains
             this requirement during the Screening period

          5. Less than 15 days with headache (migraine or non-migraine) per month in each of the 3
             months prior to the Screening Visit and maintains this requirement during the
             Screening Period.

          6. Subjects on prophylactic migraine medication are permitted to remain on therapy
             provided they have been on a stable dose for at least 3 months prior to screening
             visit and the dose is not expected to change during the course of the study.

          7. Subjects with contraindications for use of triptans may be included provided they meet
             all other study entry criteria.

        Exclusion Criteria:

          1. Subject with a history of HIV disease

          2. Subject history with current evidence of uncontrolled, unstable or recently diagnosed
             cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and
             cerebral ischemia. subjects with Myocardial Infarction (MI), Acute Coronary Syndrome
             (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient
             ischemic attack (TIA) during the 6 months prior to screening

          3. Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however
             subjects can be included who have stable hypertension and/or diabetes for at least 3
             months prior to being enrolled)

          4. Subject has a current diagnosis of major depression, other pain syndromes, psychiatric
             conditions (e.g., schizophrenia), dementia, or significant neurological disorders
             (other than migraine) that, in the Investigator's opinion might interfere with study
             assessments.

          5. Subject has a history of gastric, or small intestinal surgery (including Gastric
             Bypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has disease that
             causes malabsorption

          6. The subject has a history of current or evidence of any significant and/ or unstable
             medical conditions (e.g., history of congenital heart disease or arrhythmia, known
             suspected infection, hepatitis B or C, or cancer) that, in the investigator's opinion,
             would expose them to undue risk of a significant adverse event (AE) or interfere with
             assessments of safety or efficacy during the course of the trial.

          7. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12
             months or subjects who have met DSM-V criteria [15] for any significant substance use
             disorder within the past 12 months from the date of the screening visit.

          8. Subjects are excluded if they have previously participated in any BHV-30000
             (rimegepant) study within the last 2 years.

          9. Participation in any other investigational clinical trial while participating in this
             clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert Berman, MD</last_name>
    <phone>203-404-0410</phone>
    <email>clinicaltrials@biohavenpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Coastal Clinical Research, LLC</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauren Garner</last_name>
      <phone>251-414-1984</phone>
      <phone_ext>122</phone_ext>
      <email>Laurenb@ccr-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium, An AMR Company</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ignacio Mu√±oz</last_name>
      <phone>602-910-3343</phone>
      <email>Ignacio.Munoz@crctrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Lending</last_name>
      <phone>520-885-6793</phone>
      <email>robert.lending@synexus-us.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Health Center for Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oksana Karjala</last_name>
      <phone>501-224-1348</phone>
      <email>okkarjala@bhccr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Woodland International Research Group, LLC</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Poole</last_name>
      <phone>501-221-8681</phone>
      <email>ashley@woodlandintlresearchgrp.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Badgett</last_name>
      <phone>818-705-7451</phone>
      <email>lbadgett@priresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Cardenas, MD</last_name>
      <phone>619-567-1550</phone>
      <email>ccardenas@estudysite.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nirav Patel</last_name>
      <phone>562-304-1742</phone>
      <email>niravpatel@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mellissa Henry, RN</last_name>
      <phone>714-827-3667</phone>
      <email>mhenry@priresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synergy San Diego</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayanka Barath</last_name>
      <phone>619-327-0155</phone>
      <phone_ext>120</phone_ext>
      <email>barathm@synergysandiego.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>My-Linh Tong</last_name>
      <phone>949-752-7936</phone>
      <email>mtong@priresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Optimus Medical Group</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Felsot</last_name>
      <phone>415-423-4055</phone>
      <email>sfelsot@studyops.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Galdes</last_name>
      <phone>925-930-7267</phone>
      <email>egaldes@diabloclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yvette Strong</last_name>
      <phone>203-737-2506</phone>
      <email>yvette.strong@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ki Health Partners LLC DBA New England Institute for Clinical Research</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Valentin</last_name>
      <phone>203-914-1903</phone>
      <email>Grace@neicr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerri Wilks, MD</last_name>
      <phone>954-455-5757</phone>
      <email>kwilks@mdclinical.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AGA Clinical Trials</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Aguirre</last_name>
      <phone>305-819-1551</phone>
      <email>RAGUIRRE@AGACLINICALTRIALS.COM</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multi-Specialty Research Associates, Inc.</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauri Adams</last_name>
      <phone>386-438-8977</phone>
      <phone_ext>102</phone_ext>
      <email>lauri@msrainc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qps Mra, Llc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Kohrman, MD</last_name>
      <phone>305-598-3125</phone>
      <email>Karol.keller@qps.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Brown</last_name>
      <phone>407-425-5100</phone>
      <email>pbrown@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ormond Medical Arts Pharmaceutical Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Shoemaker, DO</last_name>
      <phone>386-236-2456</phone>
      <email>jshoemaker@ormondmedicalarts.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synexus</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Nelson</last_name>
      <phone>404-255-6005</phone>
      <email>Tamara.Nelson@synexus-us.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta, LLC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Ambrosetti</last_name>
      <phone>404-537-1281</phone>
      <email>Maria@iResearchAtlanta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B. Willow Chanthavong</last_name>
      <phone>912-790-4837</phone>
      <email>bchanthavong@mcrmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates LLC</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Thome</last_name>
      <phone>316-689-6629</phone>
      <email>cthome@heartlandresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Thome</last_name>
      <phone>316-689-6629</phone>
      <email>cthome@heartlandresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cresent City Headache and Neurology Center LLC</name>
      <address>
        <city>Chalmette</city>
        <state>Louisiana</state>
        <zip>70043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Redillas, MD</last_name>
      <phone>504-301-1468</phone>
      <email>CAYO591@ATT.NET</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramon Vargas, MD</last_name>
      <phone>504-821-8158</phone>
      <phone_ext>246</phone_ext>
      <email>RVargas@noccr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tyler Hastings</last_name>
      <phone>504-336-2667</phone>
      <email>thastings@delricht.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Ravelson</last_name>
      <phone>617-477-4868</phone>
      <email>jravelson@bostontrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NECCR Primacare Research, LLC</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02721</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Bergeron</last_name>
      <phone>508-627-7450</phone>
      <phone_ext>36</phone_ext>
      <email>mbergeron@neccr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research Network/Milford Emergency Associates, Inc</name>
      <address>
        <city>Marlborough</city>
        <state>Massachusetts</state>
        <zip>01752</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Raffa</last_name>
      <phone>508-473-5500</phone>
      <email>Lraffa@milfordwalkin.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute, Inc.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Lockrem</last_name>
      <phone>763-744-1140</phone>
      <phone_ext>320</phone_ext>
      <email>susan.lockrem@criminnesota.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute, Inc.</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Lockrem</last_name>
      <phone>763-744-1140</phone>
      <phone_ext>320</phone_ext>
      <email>susan.lockrem@criminnesota.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Colgan</last_name>
      <phone>816-943-0770</phone>
      <email>clinical@cprkc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sundance Clinical Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Tesson</last_name>
      <phone>314-576-3377</phone>
      <email>stesson@sundanceclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>StudyMetrix Research, LLC</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Rocco</last_name>
      <phone>636-387-5100</phone>
      <email>recruitment@studymetrix.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alisha Kiepke</last_name>
      <phone>402-371-0797</phone>
      <email>akiepke@mcrmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Brudon</last_name>
      <phone>856-753-7335</phone>
      <email>dbrudon@hritrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Galindo</last_name>
      <phone>505-224-7407</phone>
      <phone_ext>223</phone_ext>
      <email>lgalindo@abqct.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPRI Clinical Trials, LLC</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana Tsiporin</last_name>
      <phone>718-616-2230</phone>
      <email>ttsiporin@spristudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNS Research Science, Inc.</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lela Tisdale</last_name>
      <phone>718-969-3005</phone>
      <email>Lela.Tisdale@synexus-us.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Davis, MD</last_name>
      <phone>585-288-0890</phone>
      <email>mdavis@rcrclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PharmQuest, LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randal Von Seggern</last_name>
      <phone>336-574-8020</phone>
      <email>rvonseggern@pharmquest.biz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trent Holmes</last_name>
      <phone>919-390-7193</phone>
      <email>trent.holmes@pmg-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilmington Health, PLLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Harding</last_name>
      <phone>336-714-2641</phone>
      <email>legal@pmg-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Murphy</last_name>
      <phone>614-294-3854</phone>
      <email>Melissa.Murphy@synexus-us.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Ellis</last_name>
      <phone>937-424-1050</phone>
      <email>mellis@midwestclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hometown Urgent Care and Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ritu Singla</last_name>
      <phone>937-912-4444</phone>
      <email>rsingla@hometownurgentcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurology Diagnostics, Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin McKeen</last_name>
      <phone>937-224-8200</phone>
      <phone_ext>option 5</phone_ext>
      <email>research@neurologydiagnostics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Arora, MD</last_name>
      <phone>614-336-7880</phone>
      <email>SArora@aventivresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Summit Research Network (Oregon) Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tawnya Andersen</last_name>
      <phone>503-279-8252</phone>
      <email>tandersen@summitnetwork.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Philadelphia, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Long</last_name>
      <phone>215-676-6696</phone>
      <email>helen@phillyresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Morton</last_name>
      <phone>843-352-6977</phone>
      <email>nmorton@coastalcarolinaresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Dakota Dunes</city>
        <state>South Dakota</state>
        <zip>57049</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Knight</last_name>
      <phone>605-232-9000</phone>
      <email>jknight@mcrmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Rushing</last_name>
      <phone>865-305-9100</phone>
      <phone_ext>234</phone_ext>
      <email>ARUSHING@NOCCR.COM</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mullen</last_name>
      <phone>615-329-0197</phone>
      <email>Karen@CRAnashville.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nashville Neuroscience Group</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilton Rivers</last_name>
      <phone>615-284-4680</phone>
      <email>wrivers@nashvilleneuroscience.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Pickrell, MD</last_name>
      <phone>512-388-5717</phone>
      <email>ppickrell@tektonresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Dallas, LP</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Ashmore</last_name>
      <phone>214-369-2600</phone>
      <email>erina@fstrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group, LLC</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Edison</last_name>
      <phone>817-348-0228</phone>
      <email>lorenaeidson@ventaviaresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Center for Drug Development, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zohair Hariananwala</last_name>
      <phone>713-838-2022</phone>
      <phone_ext>213</phone_ext>
      <email>Zohair.harianawala@tcddresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Red Star Research</name>
      <address>
        <city>Lake Jackson</city>
        <state>Texas</state>
        <zip>77566</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Schenck</last_name>
      <phone>979-529-9440</phone>
      <email>Donna.redstarresearch@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shivani Shah</last_name>
      <phone>281-517-0550</phone>
      <email>Shivani@dmclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penny Amos</last_name>
      <phone>434-817-2442</phone>
      <email>penny@cvillemedresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tidewater Integrated Medical Research</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Hasse, MD</last_name>
      <phone>757-233-9280</phone>
      <email>ghaase@timresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arifulla Khan, MD</last_name>
      <phone>425-453-0404</phone>
      <email>study@nwcrc.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Women's: Health, Research, Gynecology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shann Emerald</last_name>
      <phone>206-522-3330</phone>
      <email>semerald@seattlewomens.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Specialists, Inc.</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Agaiby, Pharm D</last_name>
      <phone>262-925-1280</phone>
      <phone_ext>204</phone_ext>
      <email>eagaiby@cisresearch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Migraine</keyword>
  <keyword>phonophobia</keyword>
  <keyword>photophobia</keyword>
  <keyword>nausea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

